首页> 中文期刊> 《生物科学与医学(英文)》 >Labor Induction with Oral Misoprostol in Term Pregnancy: A Clinical Trial

Labor Induction with Oral Misoprostol in Term Pregnancy: A Clinical Trial

         

摘要

Introduction: Induction of labor has become an increasingly utilized obstetric intervention in developed countries. It contributes to reduce the maternal and perinatal morbidity and mortality. Dinoprostone derivatives are often used under cardiotocography. In poor countries, health structures have neither fetal monitoring, nor means of preserving Dinoprostone derivatives. Misoprostol therefore constitutes an alternative. This study seeks to establish the efficacy and safety of oral Misoprostol and to assess maternal and perinatal prognosis in an area with limited resource. Methods: This is a multi-center clinical trial, conducted in 3 hospitals centers in Kisangani, Tshopo Province/Democratic Republic of Congo from December 1, 2020 to May 31, 2021. Our sample was constituted with 68 pregnant women with term pregnancy. Fifty micrograms of Misoprostol was administered orally. The data were collected prospectively, their encoding was carried out on an Excel sheet 2013 and their analysis carried out using the EPI INFO software. Results: The average age of the pregnant women was 23.17 ± 5.76 years. The average parity was 1.02 ± 1.2. The average body mass index (BMI) was 24.98 ± 2.55 Kg/m2. 66 (97.1%) patients had received a maximum of 3 doses of Misoprostol. Out of the 16 parturients who received 3 doses or more, 11 (68.8%) had a BMI ≥ 25. The average duration of labor was 16.03 ± 7.99 hours. 66 (97.1%) pregnant women had delivered vaginally. 57 (83.8%) patients delivered within 24 hours. Out of the 11 patients who delivered after 24 hours, 7 (63.6%) had a BMI ≥ 25. The induction failure rate was 2.9% (2 patients). 2 (2.9%) fetuses had presented pathological modification of fetal heart rate (FHR). 2 (2.9%) patients had undergone cesarean section. Conclusion: Labor induction with oral Misoprostol is effective and associated with low maternal and perinatal morbidity. A BMI ≥ 25 kg/m2 increases the number of doses to be given and the duration of labor.

著录项

  • 来源
    《生物科学与医学(英文)》 |2021年第10期|P.74-88|共15页
  • 作者单位

    Department of Gynecology and Obstrics Faculty of Medecine and Pharmacy University of Kisangani Kisangani Democratic Republic of CongoCongolaise National Police Provincial Hospital of Tshopo Kisangani Democratic Republic of Congo;

    Department of Gynecology and Obstrics Faculty of Medecine and Pharmacy University of Kisangani Kisangani Democratic Republic of Congo;

    Department of Gynecology and Obstrics Faculty of Medecine and Pharmacy University of Kisangani Kisangani Democratic Republic of Congo;

    Higher Institute of Medical Techniques of Haut Uélé Isiro Democratic Republic of Congo;

    Department of Gynecology and Obstrics Faculty of Medecine and Pharmacy University of Kisangani Kisangani Democratic Republic of Congo;

    Department of Gynecology and Obstrics Faculty of Medecine and Pharmacy University of Kisangani Kisangani Democratic Republic of Congo;

    Department of Gynecology and Obstrics Faculty of Medecine and Pharmacy University of Kisangani Kisangani Democratic Republic of Congo;

    Department of Gynecology and Obstrics Faculty of Medecine and Pharmacy University of Kisangani Kisangani Democratic Republic of Congo;

    Department of Gynecology and Obstrics Faculty of Medecine and Pharmacy University of Kisangani Kisangani Democratic Republic of Congo;

  • 原文格式 PDF
  • 正文语种 chi
  • 中图分类 中国工业经济;
  • 关键词

    Misoprostol; Efficacy; Labor; BMI; Kisangani;

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号